Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Combinations in Multiple Myeloma
NCT02431208Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2015
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in multiple myeloma (MM) (11 cohorts), sponsored by Roche. Primary endpoints: Objective Response Rate up to 36 months, Recommended Phase II Dose of Lenalidomide up to 36 months and 2 more. Started Jul 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02431208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431208.